American College of Clinical Pharmacology?

The ACCP “Excellence in Achievement” Program is pleased to recognize Dr.?Kenneth Todd Moore, DBE, MS, FAHA, FCP Scientific Director, Cardiovascular Disease, Global Cardiovascular (CV) Medical Affairs, Johnson & Johnson Innovative Medicines. Kenneth ‘Todd’ Moore is a Scientific Director within Johnson & Johnson CV Global Medical Affairs. He?joined Janssen R&D in December of 2006 as a Senior Pharmacokinetic/Pharmacodynamic Scientist, prior? to which he was a Senior Clinical Scientist at Bristol-Myers Squibb PRI, working within the CV/MET drug?development programs. Within his 18 years with Johnson & Johnson, Todd has acted as the Clinical?Pharmacology Lead for several products, including IONSYS, DURAGESIC, JURNISTA, PRILIGY and?XARELTO. Todd transitioned to US-CV Medical Affairs in 2015 continuing his work with XARELTO, acting?as Scientific Director and eventually Compound Development Team Lead. During this time, he also acted?as the Scientific Director and Lead for Aprocitentan (TRYVIO), before leading the US efforts for the?Milvexian program. Todd transitioned to CV Global Medical Affairs in 2024, where he continues to?support the Milvexian program. Over his approximate 27 years within the pharmaceutical Industry, Todd has held various leadership roles?within Clinical Pharmacology and Medical Affairs with a primary focus in Factor Xa and Factor XIa?anticoagulation research. Todd is also a current member of the Bioethics Board at J&J, acts as Chair for?The American College of Clinical Pharmacology Public Policy Committee, and is a member of The Arts & Science?Dean’s Advisory Board at the Univ of Delaware. After his undergraduate degree at the Univ of?Delaware, he completed graduate degrees (MS) in Biology at Fairleigh Dickinson Univ and Research?Bioethics (MA & DBE) at Loyola Univ – Chicago. Todd is Fellow of American Heart Association and?the American College of Clinical Pharmacology. His publication history includes over 48 manuscripts,?policy papers and book chapters.

ACCP offers free CME and CPE credits to Members each month for a selected article in The Journal of Clinical Pharmacology! Non-members may obtain CE credits by accessing an entire year's worth of articles for the one-time fee of $75. https://bit.ly/3TSGkAF

Clinical Pharmacology in Drug Development (CPDD) is an international, peer-reviewed, online publication of the ACCP focused on publishing high-quality clinical pharmacology studies in drug development. https://bit.ly/39XjxMS @Wiley Clinical Health

Live Session: Tuesday, March 18th, 2025, from 12:00 to 1:00 PM ET On Demand: March 18th, 2025 to March 18th, 2028 https://lnkd.in/e44DG2U5 Why is this webinar important to your practice? Learners that complete this webinar will gain knowledge about a First-in-Class drug with a novel mechanism of action. SP-624 (generic name forvisirvat) is a small molecule activator of the sirtuin (SIRT) 6 enzyme. SIRT6 is a NAD+ dependent histone deacetylase and is believed to be the first activator of the enzyme tested in human clinical trials. It is currently being assessed in a Phase 2b/3 study for the treatment of major depressive disorder. The webinar presents data from single ascending dose and multiple ascending dose studies conducted in healthy male and female subjects. The safety, tolerability and pharmacokinetics after single multiple doses of forvisirvat will be reviewed. Target Audience: Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals, including Clinical Pharmacologists and Allied Health Services, who are involved or interested in the dosing of Sirtuin 6 Activator SP-624. Learning Objectives After completing this activity, the learner will be able to: Describe the pharmacokinetics of SP-62; Identify key characteristics of dose estimation via ascending dose response of Sirtuin 6 Activator; Describe the safety assessments based on the adverse events, serious adverse events and treatment emergent adverse events (TEAEs) of Sirtuin 6 Activator; Discuss the use of pharmacokinetics in early drug development.

The?American College of Clinical Pharmacology??(ACCP) is pleased to announce the publication of?"Sentinel Dosing - Time for a Risk-Based Approach?"?in the March 2025 issue of ACCP's?The Journal of Clinical Pharmacology. https://lnkd.in/eBQRzkRR.

ACCP offers free CME and CPE credits to Members each month for a selected article in The Journal of Clinical Pharmacology! Non-members may obtain CE credits by accessing an entire year's worth of articles for the one-time fee of $75. https://bit.ly/3TSGkAF

The?American College of Clinical Pharmacology??(ACCP)?invites you to?Submit an Abstract!?Present your research in a Poster & network with a global audience of healthcare professionals in the field of clinical pharmacology representing academia, industry, regulatory agencies and clinical practice. https://lnkd.in/en-63iNv The top eight Student & Trainee (STEP) Abstracts plus the top two Early-stage Professional (ESP) Abstracts will be honored in the ACCP Abstract Awards Program?which provides a $1,000 honorarium, a trophy and complimentary registration for the 3-day Annual Meeting, plus up to $500 in reimbursable travel support. STEP Abstracts ranking 9-16 in scores will also receive up to $500 in reimbursable travel support. In addition, ACCP will provide?up to $3,000 in travel support for the top scoring Student & Trainee and the top scoring Early-stage Professional Abstracts accepted from a Developing Country! To be eligible for this Travel Grant, the recipient must comply with the following: The recipient must be a Student/Trainee (including postdoctoral fellows) or Early-stage Professional (first 10 years of a full time professional position). The recipient must be the primary author of the Abstract and live in a developing country categorized as low income or lower middle income by the World Bank (current list of countries). The Abstract must be submitted by the April 11th?deadline. Travel Grants are contingent upon the recipient attending the ACCP Annual Meeting and presenting the Poster. The Abstract Submission must be one of the top two scored Abstracts?and the author is required to apply for the travel grant. For attendees from?developing countries, discounted registration fees will be available to Poster Presenters and other colleagues interested in attending the Annual Meeting.??More information will be available in April when registration opens. https://lnkd.in/en-63iNv

Live Session: Tuesday, March 18th, 2025, from 12:00 to 1:00 PM ET On Demand: March 18th, 2025 to March 18th, 2028 https://lnkd.in/e44DG2U5 Why is this webinar important to your practice? Learners that complete this webinar will gain knowledge about a First-in-Class drug with a novel mechanism of action. SP-624 (generic name forvisirvat) is a small molecule activator of the sirtuin (SIRT) 6 enzyme. SIRT6 is a NAD+ dependent histone deacetylase and is believed to be the first activator of the enzyme tested in human clinical trials. It is currently being assessed in a Phase 2b/3 study for the treatment of major depressive disorder. The webinar presents data from single ascending dose and multiple ascending dose studies conducted in healthy male and female subjects. The safety, tolerability and pharmacokinetics after single multiple doses of forvisirvat will be reviewed. Target Audience: Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals, including Clinical Pharmacologists and Allied Health Services, who are involved or interested in the dosing of Sirtuin 6 Activator SP-624. Learning Objectives After completing this activity, the learner will be able to: Describe the pharmacokinetics of SP-62; Identify key characteristics of dose estimation via ascending dose response of Sirtuin 6 Activator; Describe the safety assessments based on the adverse events, serious adverse events and treatment emergent adverse events (TEAEs) of Sirtuin 6 Activator; Discuss the use of pharmacokinetics in early drug development.

ACCP has a variety of Live, On Demand and text-based online CE resources available for completion for your professional development. Visit ACCP Continuing Education to learn more or select from any of the On Demand courses bit.ly/3FBV1zD

Check out the ACCP Job Ctr for current job listings and find your ideal opportunity! https://bit.ly/48yxywv #Careers #ACCPJobCtr #DreamJob